Mumbai: Blue Jet Healthcare Ltd., a leading manufacturer of specialty pharmaceutical and healthcare ingredients, reported a mixed set of financial results for the first quarter of FY27. While the company witnessed a year-on-year decline in revenue and profit, it delivered a strong sequential recovery, supported by improved operational efficiency and a healthy EBITDA margin.
The Q1 FY27 performance reflects the company’s ability to maintain strong profitability despite lower sales compared with the corresponding quarter last year.
Blue Jet Healthcare Q1 FY27 Financial Highlights
Blue Jet Healthcare reported revenue from operations of ₹293.15 crore for Q1 FY27, compared with ₹354.76 crore in the same quarter last year, registering a 17.37% year-on-year decline. However, revenue increased 24.92% quarter-on-quarter, indicating a strong recovery from the previous quarter.
The company’s EBITDA stood at ₹113.30 crore, down 8.77% YoY from ₹124.19 crore. On a sequential basis, EBITDA rose 25.71%, reflecting improved business momentum.
Despite lower EBITDA on a yearly basis, the company delivered better operating efficiency. EBITDA margin improved to 38.65%, compared with 35.01% in Q1 FY26 and 38.42% in the previous quarter.
Blue Jet Healthcare Profit Before Tax and Net Profit
Profit Before Tax (PBT) came in at ₹105.95 crore, compared with ₹122.86 crore in the year-ago quarter, a decline of 13.77% YoY. Sequentially, PBT increased 21.62%.
Net Profit (PAT) stood at ₹78.26 crore, down from ₹91.17 crore in Q1 FY26, representing a 14.16% year-on-year decline. Compared with the previous quarter, PAT increased 21.63%, highlighting an improvement in earnings momentum.
The company’s earnings per share (EPS) declined to ₹4.51 from ₹5.26 a year earlier but improved from ₹3.71 in the March quarter.
Blue Jet Healthcare Margin Strength Remains a Key Positive
Although revenue declined on a year-on-year basis, Blue Jet Healthcare maintained a strong operating profile.
An EBITDA margin of 38.65% is among the highest in the specialty chemicals and pharmaceutical ingredients sector. The improvement in margin despite lower revenue indicates better product mix, pricing discipline, and effective cost management.
This operational resilience helped cushion the impact of weaker sales on profitability.
Outlook
Blue Jet Healthcare continues to focus on high-value pharmaceutical intermediates, contrast media intermediates, and specialty ingredients supplied to global healthcare companies.
Going forward, investors will closely watch:
– Recovery in revenue growth.
– Demand from international pharmaceutical customers.
– Sustainability of EBITDA margins.
– Expansion of specialty product offerings.
– Export performance and order pipeline.
The company’s ability to maintain industry-leading margins while restoring top-line growth will be a key factor driving future earnings.
Conclusion
Blue Jet Healthcare reported a mixed Q1 FY27 performance, with revenue declining 17.37% and net profit falling 14.16% year-on-year. However, the company recorded a strong sequential recovery across revenue, EBITDA, PBT, and PAT.
The standout feature of the quarter was the improvement in EBITDA margin to 38.65%, demonstrating continued operational strength despite softer revenue.
If demand improves in the coming quarters while margins remain strong, Blue Jet Healthcare could be well-positioned to deliver better financial performance over the rest of FY27.
Also see